Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica

Vaccine

Volumn 33, Issue 18, 2015, Pages 2141-2151

  Gonzalez, Paula ^a,b   Hildesheim, Allan ^c   Herrero, Rolando ^b   Katki, Hormuzd ^c   Wacholder, Sholom ^c   Porras, Carolina ^a   Safaeian, Mahboobeh ^c   Jimenez, Silvia ^b   Darragh, Teresa M ^d   Cortes, Bernal ^a   Befano, Brian ^e   Schiffman, Mark ^c   Carvajal, Loreto ^a   Palefsky, Joel ^d   Schiller, John ^c   Ocampo, Rebeca ^a   Schussler, John ^e   Lowy, Douglas ^c   Guillen, Diego ^a   Stoler, Mark H ^f   Quint, Wim ^g   Morales, Jorge ^a   Avila, Carlos ^a   Rodriguez, Ana Cecilia ^a   Kreimer, Aimée R ^c   more..

^a PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g DDL DIAGNOSTIC LABORATORY   (Netherlands)

Author keywords

Human papillomavirus; Long term follow up; Methods; Vaccines

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; RECOMBINANT HEPATITIS B VACCINE; WART VIRUS VACCINE;

ADULT; ALGORITHM; ARTICLE; CANCER SCREENING; CLINICAL EVALUATION; COLPOSCOPY; CONTROLLED STUDY; COSTA RICA; CROSSOVER PROCEDURE; FEMALE; FOLLOW UP; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; LONG TERM FOLLOW UP; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL INTERCOURSE; SEXUALITY; STUDY DESIGN; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY CANCER DIAGNOSIS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; PAPILLOMAVIRUS INFECTIONS; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COSTA RICA; CROSS-OVER STUDIES; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A VACCINES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RESEARCH DESIGN; TIME FACTORS; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84926421841     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.015     Document Type: Article

References (35)

1. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al. F.GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11 2013, International Agency for Research on Cancer, Lyon, France, Available from: 〈http://globocan.iarc.fr〉 (accessed on 19/09/2014) [Internet].
2. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005, 6(4):204.
3. de Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13(6):607-615. 10.1016/S1470-2045(12)70137-7.
4. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056. 10.1016/S1470-2045(10)70230-8.
5. Alemany L., Saunier M., varado-Cabrero I., Quiros B., Salmeron J., Shin H.R., et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2014, (May). 10.1002/ijc.28963.
6. de S.S., Alemany L., Ordi J., Tous S., Alejo M., Bigby S.M., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013, 49(Nov (16)):3450-3461. 10.1016/j.ejca.2013.06.033.
7. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13(1):89-99. 10.1016/S1470-2045(11)70286-8.
8. Munoz N., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102(Mar (5)):325-339. 10.1093/jnci/djp534.
9. Herrero R., Hildesheim A., Rodriguez A.C., Wacholder S., Bratti C., Solomon D., et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008, 26(Sep (37)):4795-4808. 10.1016/j.vaccine.2008.07.002.
10. Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Gonzalez P., Kreimer A.R., et al. Prevention of persistent human papillomavirus (HPV) infection by a HPV 16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery 2011, 1(Oct (5)):408-419. 10.1158/2159-8290.CD-11-0131.
11. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199(Apr (7)):926-935. 10.1086/597307.
12. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13(1):100-110. 10.1016/S1470-2045(11)70287-X.
13. Hildesheim A., Wacholder S., Catteau G., Struyf F., Dubin G., Herrero R., et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014, 32(Sep (39)):5087-5097. 10.1016/j.vaccine.2014.06.038.
14. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298(Aug (7)):743-753.
15. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV 16/18 vaccine. J Natl Cancer Inst 2011, 103(Oct (19)):1444-1451. 10.1093/jnci/djr319.
16. Safaeian M., Porras C., Pan Y., Kreimer A., Schiller J.T., Gonzalez P., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013, 6(11):1242-1250. 10.1158/1940-6207.CAPR-13-0203.
17. Herrero R., Quint W., Hildesheim A., Gonzalez P., Struijk L., Katki H.A., et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 2013, 8(7):e68329. 10.1371/journal.pone.0068329.
18. Kreimer A.R., Gonzalez P., Katki H.A., Porras C., Schiffman M., Rodriguez A.C., et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011, 12(9):862-870. 10.1016/S1470-2045(11)70213-3.
19. Kemp T.J., Hildesheim A., Safaeian M., Dauner J.G., Pan Y., Porras C., et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011, 29(Mar (11)):2011-2014. 10.1016/j.vaccine.2011.01.001.
20. Safaeian M., Porras C., Schiffman M., Rodriguez A.C., Wacholder S., Gonzalez P., et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010, 102(Nov (21)):1653-1662. 10.1093/jnci/djq384.
21. Rodriguez A.C., Solomon D., Herrero R., Hildesheim A., Gonzalez P., Wacholder S., et al. Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol 2013, 178(Sep (5)):752-760. 10.1093/aje/kwt047.
22. WHO WHO position paper. Human papillomavirus vaccines. Wkly Epidemiol Rec 2009, 84:118-131.
23. Markowitz L., Dunne E., Saraiya M., Chesson H., Curtis C.R., Gee J., et al. Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014, 63(Jul (29)):620-624.
24. Cortes B., Schiffman M., Herrero R., Hildesheim A., Jimenez S., Shea K., et al. Establishment and operation of a biorepository for molecular epidemiologic studies in Costa Rica. Cancer Epidemiol Biomarkers Prev 2010, 19(4):916-922. 10.1158/1055-9965.EPI-10-0066.
25. Baay M.F., Quint W.G., Koudstaal J., Hollema H., Duk J.M., Burger M.P., et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 1996, 34(3):745-747.
26. Van Doorn L.J., Molijn A., Kleter B., Quint W., Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006, 44(9):3292-3298.
27. Sullivan G.M., Feinn R. Using effect size-or why the P value is not enough. J Grad Med Educ 2012, 4(Sep (3)):279-282. 10.4300/JGME-D-12-00156.1.
28. Rothman K.J., Boice J.D. Epidemiologic Analysis with a Programmable Calculator 1982, Epidemiology Resources, Inc., Boston, MA. New Edition.
29. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42(Mar (1)):121-130.
30. Lehtinen M., Apter D., Dubin G., Kosunen E., Isaksson R., Korpivaara E.L., et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006, 17(8):517-521.
31. Lehtinen M., Idanpaan-Heikkila I., Lunnas T., Palmroth J., Barr E., Cacciatore R., et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 2006, 17(4):237-246.
32. Petaja T., Pedersen C., Poder A., Strauss G., Catteau G., Thomas F., et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011, 129(Nov (9)):2147-2157. 10.1002/ijc.25887.
33. Naud P.S., Roteli-Martins C.M., de Carvalho N.S., Teixeira J.C., de Borba P.C., Sanchez N., et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014, 10(Jun (8)):2147-2162.
34. Roteli-Martins C.M., Naud P., De B.P., Teixeira J.C., de Carvalho N.S., Zahaf T., et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012, 8(3):390-397. 10.4161/hv.18865.
35. Schwarz T.F., Huang L.M., Lin T.Y., Wittermann C., Panzer F., Valencia A., et al. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10-14 year old girls: open six-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J 2014, 33(Jun (12)):1255-1261.